The influence and safety of denosumab on bone mineral density of lumbar spine in women with low bone mass: a meta-analysis.
- Author:
Xiaowen ZHU
1
;
Jianting CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Antibodies, Monoclonal, Humanized; adverse effects; pharmacology; Bone Density; drug effects; Bone Density Conservation Agents; adverse effects; pharmacology; Denosumab; Female; Humans; Lumbar Vertebrae; Randomized Controlled Trials as Topic
- From: Journal of Southern Medical University 2013;33(6):913-917
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the influence and safety of denosumab on bone mineral density (BMD) of lumbar spine in women with low bone mass.
METHODSThe clinical literatures concerning denosumab for the treatment of osteopenia or osteoporosis in women were searched from Medline, Embase, Cochrane Central Register of Controlled Trials, Wanfang database, China National Knowledge Infrastructure database, Chinese Biomedical Database. Randomized controlled trials (RCT) were selected by the inclusive and exclusive criteria. The jadad scale was used in the quality assessment of included studies. Meta-analysis of valid data picked from included studies was performed by RevMan 5.0.24 software.
RESULTS5 RCT were included in this meta-analysis. The results of meta-analysis using the fixed effects model showed that, the increase level of lumbar BMD after 12 month was 5.45% (95% CI, 5.05%~5.84%) higher in denosumab group than in placebo control group (P<0.00001). The serious adverse event, serious infection event and pack pain occurred during the followed-up were analysed using fixed effects model. The results showed no significant difference between two groups.
CONCLUSIONCompared with placebo control group, denosumab can significant increase the BMD of lumbar spine, and the safety of two groups is similar.
